Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 05, 2015 1:50 AM ET

Pharmaceuticals

Company Overview of HUYA Bioscience International, LLC

Company Overview

HUYA Bioscience International, LLC engages in identifying and licensing pre-clinical and clinical stage compounds in China. It engages in accelerating the development of biopharmaceutical product opportunities originating in China. The company offers HBI-8000, a histone deacetylases inhibitors for cancer; HBI-3000, a multi-ion channel blocker for the treatment of arrhythmia; and HBI-3802, a small molecule for improving heart function, as well as stimulates cardiac stem cell differentiation into functional cardiomyocytes, and replaces and remodels dead myocardium with new functional tissues. The company has a strategic alliance with China Wuqing Development Area. HUYA Bioscience International...

12531 High Bluff Drive

Suite 138

San Diego, CA 92130

United States

Founded in 2004

Phone:

858-798-8800

Fax:

858-798-8888

Key Executives for HUYA Bioscience International, LLC

Founder, Executive Chairman, Chief Executive Officer and President
Age: 50
Chief Financial Officer
Age: 49
Chief Technology Officer and Chief Operating Officer of Asia
Chief Scientific Officer and Executive Vice President
Age: 54
Head of Therapeutics China
Compensation as of Fiscal Year 2014.

HUYA Bioscience International, LLC Key Developments

HUYA Bioscience International Completes First Cohort in Phase 1 Clinical Trial of HBI-8000 in Japan

HUYA Bioscience International has completed the first cohort in a Phase 1 clinical trial in Japan of its cancer drug HBI-8000, a novel oral histone deacetylase inhibitor. This follows acceptance by the Pharmaceutical and Medical Devices Agency (PMDA) of the company's accelerated development strategy in Japan. The Phase 1 open-label, dose escalation trial is evaluating the safety and pharmacokinetics of HBI-8000 in Japanese patients with non `Hodgkin's lymphoma. The first cohort received HBI-8000 tablets twice weekly, with no dose-limiting toxicities observed. The second cohort is now underway with a higher dose. The trial is designed to establish a maximum tolerated dose (MTD) to proceed to Phase 2 trials for the treatment of adult T-cell leukemia/lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) in Japan. The clinical development of HBI-8000 in Japan leverages clinical data from Chinese clinical trials through the Tripartite Cooperation on Health between China, South Korea and Japan. Shenzhen Chipscreen Biosciences recently announced the approval of chidamide in China as the world's first oral HDAC inhibitor for the treatment of relapsed or refractory PTCL. HUYA holds exclusive rights to chidamide (HBI-8000) worldwide, excluding China, and is developing the compound for hematological malignancies and solid tumors.

HUYA Bioscience International, LLC Names Alain Rolland as Executive Vice President and Chief Scientific Officer

HUYA Bioscience International, LLC announced a key addition to its executive team. Alain Rolland, Pharm.D., Ph.D., has been appointed as Executive Vice President and Chief Scientific Officer. Dr. Rolland brings 25 years of international leadership experience in the biopharma industry, including positions at Ciba-Geigy, Galderma, GeneMedicine, Valentis, and Vical. Most recently, Dr. Rolland was a Corporate Officer and Executive Vice President of Product Development at Vical.

Huya Bioscience International Announces Joint Venture with Tianjin Institute of Pharmaceutical Research to Develop Medical Technologies and Therapies for Global Markets

Huya Bioscience International (US and China) has announced a joint venture with Tianjin Institute of Pharmaceutical Research (TIPR) to develop medical technologies and therapies for global markets. The joint venture will focus on developing China-sourced novel biopharmaceuticals for global markets. Under the agreement, Huya and TIPR will share the decision-making on product development and commercialisation equally and focus initially on the China market before also targeting international markets.

Similar Private Companies By Industry

Company Name Region
CanDiag, Inc United States
Esi Lederle Inc United States
T-19 Inc United States
Vitaelin Nutraceuticals, LLC United States
Schering Berlin, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HUYA Bioscience International, LLC, please visit www.huyabio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.